未登录

E

Emily Brouwer

University of Wisconsin System

H指数:7

被引数:215

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Use of Reporting Recommendation Intended for Pharmaceutical Risk Minimisation Evaluation Studies (RIMES) Checklist in Risk Minimisation/Mitigation Studies: A Review and Survey

IF3.8

2024-12-171

PRE

Comparing regulatory guidance on risk minimization/mitigation and the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies checklist

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2024-09-190

PRE

Early Diagnosis of Primary Immunodeficiency Disease Using Clinical Data and Machine Learning

使用临床数据和机器学习对原发性免疫缺陷病进行早期诊断

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE

IF6.6

2022-11-0112

OAAI

Predictors of chronic opioid therapy in Medicaid beneficiaries with HIV who initiated antiretroviral therapy

SCIENTIFIC REPORTS

IF3.9

2021-07-290

OAAI

Signal Detection and Methodological Limitations in a Real-World Registry: Learnings from the Evaluation of Long-Term Safety Analyses in PSOLAR

IF3.8

2021-06-0210

OAAI

Incidence of von Willebrand disease in Denmark, 1995-2016: A cohort study

IF3

2021-02-064

PREAI

Molecular approach to the classification of chronic fibrosing lung disease-there and back again

VIRCHOWS ARCHIV

IF3.1

2020-11-092

OAAI

ANALYSIS OF PULMONARY-RELATED CLINICAL MANIFESTATIONS AND HEALTH RESOURCE UTILIZATION IN PATIENTS WITH SEVERE AND NON-SEVERE ALPHA-1 ANTITRYPSIN DEFICIENCY IN THE UNITED STATES

IF8.6

2019-10-010

PREAI

Real-World Evidence: What It Is and What It Can Tell Us According to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness Research (CER) Special Interest Group (SIG)

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2018-05-0729

OAAI